Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | HTR3A | P46098 | 3/20 | 0.39 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | RHEB | Q15382 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541411 | 0.89 | MEN1 (0.47) | PDE7AMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL3544118 | 0.89 | HTR1A (0.44) | PDE7AMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL3543388 | 0.88 | ALDH1A1 (0.40) | PDE7AMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL13239537 | 0.82 | LMNA (0.53) | PDE7AMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL3544040 | 0.79 | MAPK14 (0.39) | ALDH1A1MAPK14MAPK13 | |
| SCHEMBL3543373 | 0.76 | ATM (0.43) | PDE7AKDM4EMAPK14MAPK13 | |
| SCHEMBL15208335 | 0.76 | MAPK14 (0.49) | PDE7AMAPK14KCNQ3KCNQ2MAPK13 | |
| SCHEMBL3547054 | 0.75 | MAPK14 (0.40) | MAPK14MAPK13 | |
| SCHEMBL30032237 | 0.74 | ADRA2A (0.36) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2714643 | 0.74 | ADRA2A (0.36) | MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732463-B2 | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2010-06-08 | — | — | US | disclosed |
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | H.LUNDBECK A/S (DK) | 2006-05-11 | — | — | US | disclosed |
| EP-1626720-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. Lundbeck A/S (DK) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004087156-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | HTR4, HTR5A, TPH1 | PDE7A 711/4885MAPT 2875/4885KDM4E 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.